Navigation Links
Pharmaxis Investor Conference Call
Date:4/6/2009

SYDNEY, Australia, April 6 /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS; Nasdaq: PXSL) will release its March 2009 Quarterly Report to Shareholders on the afternoon of Wednesday 8th April 2009. Dr Alan Robertson will host an investor teleconference the following morning to review the quarter and answer investor questions.

The teleconference will be on Thursday 9th April at 8.00am (Sydney), (Wednesday 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West Coast).

    Telephone access (toll free) details are below:
    -- Australia: 1800 131 617
    -- USA/Canada:  866 746 2596
    -- UK: 0800 376 8339
    -- NZ: 0800 446 958
    -- Switzerland: 0800 001 230
    -- Online (global access):
      http://services.choruscall.com/links/pharmaxis090409.html

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.

    CONTACT:

     Pharmaxis Investor Relations
     Tel:     +61-2-9454-7200
     Fax:     +61-2-9451 3622,
     Email:   Investor.Relations@Pharmaxis.com.au
     Website:http://www.pharmaxis.com.au

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmaxis Appoints French Distributor for Aridol(TM)
2. Pharmaxis Builds Senior Management Team
3. Pharmaxis Investor Conference Call
4. Pharmaxis Aridol Approved for Sale in Switzerland
5. Pharmaxis Investor Conference Call
6. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
7. New Pharmaxis Board Appointment
8. Pharmaxis Aridol Authorised for Sale in Germany
9. Pharmaxis First Steps into China
10. Pharmaxis to Apply to Market Bronchitol in Australia
11. Pharmaxis Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
Breaking Biology Technology:
(Date:8/15/2017)... LLC , a medical device company focused on improving the safety ... ISO 13485 Certification, the global standard for medical device quality management ... ... for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates our ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
Breaking Biology News(10 mins):